Comparison of anti-PD-L1 with anti-PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.

被引：0
|
作者：
Li, Shaohua
Mei, Jie
Wang, Qiaoxuan
Zhao, Rongce
Lu, Lianghe
Deng, Min
Lin, Wenping
Guan, Renguo
Wen, Yuhua
Zheng, Lie
Wei, Wei
Guo, Rongping
机构：
[1] Sun Yat Sen Univ Canc Ctr, Guangzhou, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
509
引用
收藏
页码：509 / 509
页数：1
相关论文
共 50 条
  • [1] The best benefit population treated with lenvatinib plus anti-PD-1 for unresectable hepatocellular carcinoma.
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Zhang, Jihai
    Dong, Zheng
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Yang, Yongping
    Zeng, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16152 - E16152
  • [2] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [3] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [4] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Chen, Yi
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies
    Borch, Troels H.
    Donia, Marco
    Andersen, Mads H.
    Svane, Inge M.
    DRUG DISCOVERY TODAY, 2015, 20 (09) : 1127 - 1134
  • [6] Hyperprogressive disease with anti-PD-1 and anti-PD-L1
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (12): : E527 - E527
  • [7] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Lurain, Kathryn
    Ramaswami, Ramya
    Yarchoan, Robert
    Uldrick, Thomas S.
    CURRENT HIV/AIDS REPORTS, 2020, 17 (05) : 547 - 556
  • [8] ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE
    Cordova-Bahena, Luis
    Velasco-Velazquez, Marco A.
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2021, 73 (01): : 8 - 16
  • [9] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Kathryn Lurain
    Ramya Ramaswami
    Robert Yarchoan
    Thomas S. Uldrick
    Current HIV/AIDS Reports, 2020, 17 : 547 - 556
  • [10] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
    Kudo, Masatoshi
    LIVER CANCER, 2019, 8 (06) : 413 - 426
12345